Capecitabine plus pembrolizumab after TNBC surgery and chemo
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial studies whether adding capecitabine to pembrolizumab after surgery can lower the risk of cancer coming back in people with triple-negative breast cancer that didn’t fully respond to earlier treatment. It’s meant for patients whose tumor was removed but still showed remaining cancer after chemo-immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to sign study consent (or have a trusted written proxy if you can’t)
- Have triple-negative breast cancer where HER2 is negative and ER/PgR staining is under 10%
- Have had surgery removing the breast tumor and any involved lymph nodes
- Finish earlier treatment with pembrolizumab plus chemotherapy, and then have no full “pathology complete response” (RCB I–III allowed, not a complete response)
- Have good recovery and strength for treatment (ECOG score under 2) and blood/organ tests within the last 28 days
- No spread to other organs on scans or exams before starting this trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial is for people with early triple-negative breast cancer who had a strong response to chemotherapy combined with pembrolizumab before surgery. It aims to find the best way to continue using pembrolizumab after surgery to reduce the risk of cancer coming back.
This trial tests if combining the chemotherapy pill capecitabine with the immunotherapy drug camrelizumab can help people with triple-negative breast cancer (TNBC) who still have tumor tissue after initial treatment. It is for patients whose breast cancer has structures called tumor-associated lymphoid structures (TLS) and who did not achieve a complete response to neoadjuvant therapy.
This trial looks at different ways to use the chemotherapy drug capecitabine for people with triple-negative breast cancer who still have cancer cells after initial treatment and surgery. It aims to find the best approach to improve outcomes.
This trial tests if continuing pembrolizumab after surgery can help prevent breast cancer from coming back in people with triple-negative breast cancer who still had some cancer after initial chemo and pembrolizumab before surgery.
Hear when a new Triple Negative Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.